InterCure Ltd. (NASDAQ:INCR) Sees Significant Drop in Short Interest

Posted by Hanz Christensen on Jul 13th, 2026

InterCure Ltd. (NASDAQ:INCR – Get Free Report) was the target of a significant decrease in short interest during the month of June. As of June 30th, there was short interest totaling 15,144 shares, a decrease of 67.9% from the June 15th total of 47,234 shares. Based on an average trading volume of 104,980 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

InterCure Price Performance

Shares of NASDAQ:INCR traded up $0.03 during midday trading on Monday, hitting $1.00. The company’s stock had a trading volume of 605 shares, compared to its average volume of 53,264. The company has a market cap of $54.52 million, a P/E ratio of 33.23 and a beta of 1.39. InterCure has a 12-month low of $0.68 and a 12-month high of $1.77. The business’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $0.90. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.97 and a current ratio of 1.48.

InterCure (NASDAQ:INCR – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $23.15 million for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings raised InterCure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Check Out Our Latest Research Report on INCR

About InterCure

(Get Free Report)

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.